New hope for stomach cancer: experimental combo enters final trial phase
NCT ID NCT07118527
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether a new combination of drugs (SHR-A1811, adebrelimab, and chemotherapy) works better than the current standard treatment for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The study will enroll about 600 participants and measure how long they live without their cancer getting worse, as well as overall survival. The goal is to find a more effective first-line therapy for this aggressive cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-A1811 (a targeted drug) combined with adebrelimab (immunotherapy) and chemotherapy (capecitabine or fluorouracil)
- What this could lead to
- If successful, this could offer a new first-line treatment option for advanced stomach cancer, potentially improving how long patients live without their cancer growing.
- What could go wrong
- This is an early-stage phase 3 trial, so results are not yet known. The new combination may not be more effective than current standard therapy and could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Hospital of China Medical University
RECRUITINGShenyang, Liaoning, 110001, China
-
Zhongshan Hospital，Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can an immunotherapy combo shrink stomach tumors before surgery?
- Can adding immunotherapy to chemotherapy improve gastric cancer outcomes?
- Can immunotherapy outperform chemo after stomach cancer surgery?
- Can a smart drug home in on Hard-to-Treat cancers?